Stock Analiz

Caribou Biosciences, Inc. CRBU

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$0.36Market cap $39M
Open the interactive analysis →

Caribou Biosciences, Inc. (CRBU) is a healthcare company listed in the US with a market value of about $39M. In the twelve months to September 30, 2026 it had revenue of $9M and net income of -$102M, a net margin of -1085.0%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -2% a year, a 5-year average ROIC of -44%.

About Caribou Biosciences

Caribou Biosciences is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $6M in 2019 to $11M in 2025, growth of about 11.6% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 54% over three years (dilution for shareholders). It spends 981% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S4.1
P/B0.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-238.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)11.7%
Revenue growth (5 yrs, per year)-2.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-906.1%
ROIC (5-yr avg.)-44.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$9M$11M$10M$34M$14M$10M$12M$6M
Net income-$102M-$148M-$149M-$102M-$99M-$67M-$34M-$23M
Free cash flow-$93M-$112M-$143M-$105M-$97M-$35M-$34M-$33M
EPS (diluted)$-1.03$-1.59$-1.65$-1.38$-1.64$-2.11$-4.01$-2.80
Net margin-1085.0%-1327.4%-1491.9%-296.1%-717.8%-697.3%-277.6%-404.8%
ROIC—-98.9%-59.6%-23.2%-25.6%-13.6%—-347.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Caribou Biosciences pay a dividend?

Not currently.

Is Caribou Biosciences a good stock to buy?

We do not give buy or sell advice. Caribou Biosciences scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.